Based on these findings, we conclude that miR-29a/b/c suppress G1/S-phase transition and the proliferation of glioma cells by targeting TRAF4 and down-modulating the AKT/GSK-3β pathway (Fig. 8c). Here, AKT1 is linked to central nervous system cancer.